App-Quantinova.ai

Cytoreductive surgery and HIPEC in colorectal cancer peritoneal metastases (CRPM): Real-world outcomes in systemic anticancer treatment–naïve patients.

Nadina Tinsley - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Oxaliplatin

Clinical outcomes of appendix goblet cell adenocarcinoma and role of systemic chemotherapy.

Madeleine Cornelia Strach - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

Bevacizumab in first-line therapy in lung metastases of colorectal cancer: An ARCAD pooled analysis.

Einat S Shmueli - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Bevacizumab

BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC).

Scott Kopetz - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Encorafenib

Durvalumab and tremelimumab plus local tumor ablation (RFA or stereotactic radiotherapy) in patients with metastatic colorectal cancer with unresectable liver metastases: Results of the EORTC-1560-GITCG (ILOC) phase II study.

Jenny F. Seligmann - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Ticilimumab

Outcomes of patients (pts) with metastatic colorectal cancer (mCRC) participating in phase I clinical trials: The Sarah Cannon Research Institute UK experience.

Ekaterina Ignatova - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Tipiracil and trifluridine

Optimising longitudinal plasma-only circulating tumour DNA (ctDNA) for minimal residual disease (MRD) detection with combined genomic/methylation signals to predict recurrence in patients (pts) with resected stage I-III colorectal cancer (CRC) in the UK multicentre prospective study TRACC.

Susanna Slater - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

WU-NK-101, an enhanced memory natural killer (NK) cell therapy, with cetuximab (Ctx) for the treatment of advanced colorectal cancer (CRC).

John Muth - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Trastuzumab

Circulating tumor DNA (ctDNA) dynamics and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) undergoing front-line chemotherapy.

Michele Ghidini - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

The association between KRAS mutational status, clinicopathological factors including the preoperative systemic inflammatory response and outcomes in TNM stage I-III colon cancer.

Allan Matthew Golder - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

The HORIZON III retrospective exploratory analysis: HER2 expression amplification in colorectal cancer.

Fabiola Cecchi - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Bevacizumab

Association between artificial intelligence (AI) -assisted tumor AREG and EREG immunohistochemistry (IHC) and outcomes from anti-EGFR therapy during the routine management of metastatic colorectal cancer (mCRC): An observational cohort study.

Christopher Williams - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

panitumumab

Artificial intelligence-assisted evaluation of tumor infiltrating CD3+ and CD8+ T cells for prognostication and prediction of benefit from adjuvant chemotherapy in early stage colorectal cancer (CRC): A retrospective analysis of the QUASAR trial.

Christopher Williams - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Fluorouracil

Identification and characterization of four bacteriome- and mycobiome-derived subtypes in tumour and adjacent mucosa tissue of colorectal cancer patients.

Manuela Salvucci - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Association of punctate TAK1 expression with mortality in patients with microsatellite-stable colorectal cancer.

Norman James Galbraith - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Immunohistochemical assessment of COX2, P53, and beta-catenin expression to predict metachronous lesion development following polypectomy.

Mark Scott Johnstone - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

Effect of spatial transcriptomic-derived intrinsic epithelial signatures on immune cell recruitment and behaviour in the microenvironment of colorectal cancer.

Colin Wood - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

A phase 1b/2, open-label study of amivantamab monotherapy or in combination with standard-of-care chemotherapy in participants with advanced or metastatic colorectal cancer.

Paul Eliezer Oberstein - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Oxaliplatin

Durvalumab (MEDI 4736) with extended neoadjuvant regimens in rectal cancer: A randomised phase II trial (PRIME-RT).

Campbell SD Roxburgh - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Capecitabine

Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).

Markus H. Moehler - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Adrucil injection

Filters

45280 Abstracts